Bayer and Janssen to present new Xarelto data at ASH 2017

Bayer and its development partner Janssen will be presenting new drug data when attending this year's American Society of Hematology (ASH) annual meeting and exposition.

Taking place in Atlanta from December 9th to 12th, the conference will see Bayer and Janssen present a total of 13 abstracts, including a number of discussions of their oral Factor Xa inhibitor Xarelto.

The presentation will highlight data from the Select-D pilot phase III trial, showing how Xarelto can help to reduce venous thromboembolism (VTE) rates compared to low molecular weight heparin therapy in active cancer patients.

Additionally, a poster presentation will demonstrate the effectiveness and safety of Xarelto in a cohort of cancer patients with VTE from the US Truven MarketScan administrative claims database, meaning both clinical and real-world data will be shared during the conference.

Xarelto is the most broadly indicated non-vitamin K antagonist oral anticoagulant worldwide, and is approved for seven indications. In total, it has been approved in more than 130 countries.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.